MORTALITY IN A COHORT OF WOMEN GIVEN X-RAY THERAPY FOR METROPATHIA HAEMORRHAGICA
MORTALITY IN A COHORT OF WOMEN GIVEN X-RAY THERAPY FOR METROPATHIA HAEMORRHAGICA
复制标题
DOI：
10.1002/ijc.2910560606
复制
发表时间：
1994-03-15
影响因子：
6.4
通讯作者：
STOVALL, M
中科院分区：
文献类型：
--
作者：
DARBY, SC;REEVES, G;STOVALL, M
在1940-1960年间，对苏格兰2067名接受出血性都市病X射线治疗的妇女的死亡率进行了研究。平均随访时间为28年。总体而言，观察到1,313例死亡，而苏格兰的预期死亡率为1,297.01[标准化死亡率比(SMR)：1.01]。在骨盆周围器官的平均剂量在2.6-5.3Gy后，严重照射骨盆部位的癌症(照射后5年以上：1.46)的死亡率增加。对于这些癌症，照射后30年以上的SMR高于5~29年，说明照射的影响持续了30年以上，在此期间膀胱癌死亡率特别高(SMR=4.91)。白血病(SMR 2+照射后2年：2.05)、多发性骨髓瘤(SMR 5+照射后5年：2.59)的死亡率也有所增加。对于白血病，照射后30多年的SMR低于早期，但仍大于1。其他癌症的死亡率与苏格兰的死亡率相似，但乳腺癌的死亡率很低(辐射后5年以上的SMR：0.53)，即使是在辐射时50岁以上的妇女(辐射后5年以上的SMR：0.14)。这一缺陷主要是由于卵巢剂量至少为5GY的女性乳腺癌的大量缺陷所致。(C)1994年Wiley-Liss，Inc.
Mortality to January 1, 1991, has been studied in 2,067 women in Scotland given X-ray therapy for metropathia haemorrhagica during the period 1940-1960. Average follow-up was 28 years. Overall, 1,313 deaths were observed compared with 1,297.01 expected from Scottish rates [standardized mortality ratio (SMR): 1.01]. Mortality was increased for cancers of heavily irradiated pelvic sites (SMR 5+ years after irradiation: 1.46) following mean doses to organs in the vicinity of the pelvis in the range 2.6-5.3 Gy. For these cancers the SMR was higher 30+ years after irradiation than at 5-29 years, indicating that the effects of exposure last for over 30 years, and in this period bladder cancer mortality was exceptionally high (SMR = 4.91). Mortality was also raised for leukaemia (SMR 2+ years after irradiation: 2.05), following a mean bone-marrow dose of 1.3 Gy, and for multiple myeloma (SMR 5+ years after irradiation: 2.59). For leukaemia the SMR was lower 30+ years after irradiation than at earlier periods, but remained greater than unity. For other cancers mortality was similar to Scottish rates, except for breast cancer for which mortality was low (SMR 5+ years after irradiation: 0.53), even in women aged over 50 at irradiation (SMR 5+ years after irradiation: 0.14). The deficit was principally due to a large deficit of breast cancer in women with ovarian doses of at least 5 Gy. (C) 1994 Wiley-Liss, Inc.